Antibiotic Resistance: Bioinformatics-Based Understanding As a Functional Strategy for Drug Cite This: RSC Adv., 2020, 10, 18451 Design

Total Page:16

File Type:pdf, Size:1020Kb

Antibiotic Resistance: Bioinformatics-Based Understanding As a Functional Strategy for Drug Cite This: RSC Adv., 2020, 10, 18451 Design RSC Advances View Article Online REVIEW View Journal | View Issue Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug Cite this: RSC Adv., 2020, 10, 18451 design Umar Ndagi, *a Abubakar A. Falaki,b Maryam Abdullahi,c Monsurat M. Lawald and Mahmoud E. Soliman e The use of antibiotics to manage infectious diseases dates back to ancient civilization, but the lack of a clear distinction between the therapeutic and toxic dose has been a major challenge. This precipitates the notion that antibiotic resistance was from time immemorial, principally because of a lack of adequate knowledge of therapeutic doses and continuous exposure of these bacteria to suboptimal plasma concentration of antibiotics. With the discovery of penicillin by Alexander Fleming in 1924, a milestone in bacterial infections' treatment was achieved. This forms the foundation for the modern era of antibiotic drugs. Antibiotics such as penicillins, cephalosporins, quinolones, tetracycline, macrolides, sulphonamides, Creative Commons Attribution-NonCommercial 3.0 Unported Licence. aminoglycosides and glycopeptides are the mainstay in managing severe bacterial infections, but resistant strains of bacteria have emerged and hampered the progress of research in this field. Recently, new approaches to research involving bacteria resistance to antibiotics have appeared; these involve combining the molecular understanding of bacteria systems with the knowledge of bioinformatics. Consequently, many molecules have been developed to curb resistance associated with different bacterial infections. However, because of increased emphasis on the clinical relevance of antibiotics, the Received 15th February 2020 synergy between in silico study and in vivo study is well cemented and this facilitates the discovery of Accepted 1st May 2020 potent antibiotics. In this review, we seek to give an overview of earlier reviews and molecular and DOI: 10.1039/d0ra01484b structural understanding of bacteria resistance to antibiotics, while focusing on the recent bioinformatics This article is licensed under a rsc.li/rsc-advances approach to antibacterial drug discovery. Open Access Article. Published on 14 May 2020. Downloaded 9/27/2021 4:40:57 AM. 1. Introduction This is as a result of dose-related issues, the knowledge of the amount required to clear the organism from the system being The use of antimicrobial entities dates back to ancient civili- inadequate. Therefore, marked symptoms of bacterial infection zation1 during which a variety of naturally available healing persist until such time that a signicant amount is reached, and methods were used in curbing infections.1 Some of these symptoms begin to disappear. Exposure of bacteria to the methods require the use of moulds and plant extracts with inadequate dose of these agents is presumed as the number one characteristics antibiotic properties. This is true for compounds cause of bacterial resistance, which could be a contributing that were accidentally discovered (such as penicillin by Alex- factor to bacterial evolution and perhaps the origin of bacteria ander Fleming in 1924) and even for those that are linked to the evolution.3 knowledge handed down by successive generations; Egyptians In the 1940s, antibiotics were major lifelines for treating applied mouldy bread to infected wounds.2 serious infections,4 this was re-established by the successful use However, until the 20th century, bacterial infections were the of penicillin in controlling bacterial infections among military number one cause of human death in the developed world.2 personnel during the Second World War.5 Luria and Delbruck¨ in the year 1943, conducted a uctuation test6 and acknowl- aCentre for Trans-Sahara Disease, Vaccine and Drug Research, Ibrahim Badamasi edged that bacterial resistance arises from heritable changes in 6 Babangida University, Lapai, Niger State, Nigeria. E-mail: [email protected] the bacterial cell (mutation), which is independent of factors bDepartment of Microbiology, School of Agriculture and Applied Sciences, University of such as co-habitation of the bacterial colony with the virus. KwaZulu-Natal, Durban 4001, South Africa Despite the advantages derived from the use of penicillin, cFaculty of Pharmaceutical Sciences, Ahmadu Bello University Zaria, Kaduna State, resistance to these drugs emerged,7 such that in the 1950s, the Nigeria giant strides made in antibiotics development in the prior dSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, decade were threatened.8 In response to this, new beta (b)-lac- Durban 4001, South Africa eMolecular Modeling and Drug Design Research Group, School of Health Sciences, tam antibiotics were discovered and eventually upheld, thereby “ University of KwaZulu Natal, Westville Campus, Durban 4001, South Africa re-establishing the initial con dence of magic-use and magic This journal is © The Royal Society of Chemistry 2020 RSC Adv.,2020,10,18451–18468 | 18451 View Article Online RSC Advances Review result” antibiotics are being portrayed.5,8 Within the same Nevertheless, bacteria resistant to antibiotics might be decade, methicillin-resistant Staphylococcus aureus (MRSA) was acquired through gene mutation and by horizontal gene transfer; rst identied in the United Kingdom in 1962 and the United it can also be due to intrinsic activities resulting from inherent States in 1968.4,5 Unfortunately, resistance to most antibiotics structural or functional characteristics (Fig. 1). Unavailability of emerged in time-course4 to the extent that even the most powerful the susceptible target of a specic antibiotic is a typical example of antibiotics developed in the early 1970s like vancomycin used in intrinsic resistance, this is well represented in gram stain managing methicillin resistance in both Staphylococcus aureus (S. organism, with Gram-negative bacteria having a lower proportion aureus) and coagulase-negative staphylococci had its share of of anionic phospholipids in the cytoplasmic membrane than do resistance4,5 in the late 1970s. Gram-positive bacteria.16 This reduces the efficiency of the Ca2+ – To understand the key aspect of bacterial survival, Baym mediated insertion of daptomycin into the cytoplasmic et al. (2016) introduced microbial evolution and growth arena membrane that is required for its antibacterial activity.17 The (MEGA) – plate,9 typically used to study microbial evolution. intrinsic properties of some Gram-negative bacteria give them Their work suggests that evolution is not always led by the most protective measures that allow them to resist antibiotic effects resistant mutants; highly resistant mutant can be trapped such as antibiotic transport across the outer membrane. For behind more sensitive lineages.9 Baym concept of Petri dish example, the glycopeptide antibiotic vancomycin inhibits pepti- offers an unprecedented insight into the phenomenon of anti- doglycan cross-linking by binding to target D-Ala-D-Ala peptides, biotic resistance.10 this effect is more pronounced in Gram-positive bacteria, whereas Resistance to antibiotics is eroding the scienticeffort in in Gram-negative organisms, the drug transport across the outer keeping up the pace of antibiotics' discovery in the 21st membrane is hindered and access to the peptides in the peri- century.11 In the past (the golden era of antibiotics drug plasm is shutdown.18 The word antibiotic has become synony- discovery), resistance to antibiotics' was not too challenging,11 mous with antibacterial drugs therefore, in this article; the term this was because scientic research was coping with the chal- antibacterial refers to the antibiotic. 11 Creative Commons Attribution-NonCommercial 3.0 Unported Licence. lenges of antibiotic resistance. However, recent events in the Bioinformatics is a practical discipline that employs a range of antibiotic resistance prole have pushed most pharmaceutical computation techniques including sequence and structural industries to rededicate their efforts in developing novel mole- alignment, analyses of large collections of biological data, such as cules used in managing chronic illnesses, this approach genetic sequences, cell populations or protein samples, to make provides more nancial benets that guaranty their survival in new predictions or discover new biology.19 The application of monetary times. Thus, leading to drying up in the antibiotics bioinformatics tools and techniques in analysing the increasing pipeline and leaving behind a few potent molecules that may data generated in molecular biology, genomics, transcriptomics, limit the choice of antibiotics in curing certain disease condi- and proteomics is gaining momentum.20 Furthermore, the tions. The emergence and widespread of antibiotic-resistant quantum of information aggregated in the form of databases and This article is licensed under a pathogens is an emerging challenge in the public health literature for generating molecular proles and for collecting data domain, this requires global action with a multi-dimensional related epidemiology of pathogens has signicantly increased.21 approach that would address the fundamental challenges Therefore, the use of bioinformatics tools and techniques in Open Access Article. Published on 14 May 2020. Downloaded 9/27/2021 4:40:57 AM. inherent in curbing drug-resistance and ne-tune the lead way curbing bacteria resistance, pathogen identication and typing, to minimise drug-resistance.12 identifying markers for early diagnosis and treatment,
Recommended publications
  • Binding Kinetics Calculations of the Inclusion of Some Benzoic Acid Derivatives and Paracetamol in Β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel
    Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel To cite this version: Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Journal of Inclusion Phenomena and Macrocyclic Chemistry, Springer Verlag, 2020, 96 (3-4), pp.373-379. 10.1007/s10847-020-00976-1. hal-02922032 HAL Id: hal-02922032 https://hal.archives-ouvertes.fr/hal-02922032 Submitted on 25 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Djamel Eddine Khatmi,a, b* Belgacem Bezzina, b, c Stéphane Humbel,a a- Aix Marseille University, CNRS, Centrale Marseille, iSm2, Marseille, France b- Laboratory of Computational Chemistry and Nanostructures, University of 08 May 45 Guelma, Algeria c- Research Center in Industrial Technology (CRTI), P.O.BOX 64, Chéraga 16014, Algiers, Algeria *corresponding author: [email protected] KEYWORDS: Cyclodextrin. Inclusion complexes. Molecular dynamic simulation. Binding Kinetics. Benzoic acid derivatives. Paracetamol. ABSTRACT This theoretical study is designed to identify the main driving forces of the inclusion of some benzoic acid (BA) derivatives as well as Paracetamol (ParCM) with β-cyclodextrin (β-CD) by computing the kinetics of binding.
    [Show full text]
  • 28912 Oxoid FDA Cartridge Tables:1
    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
    [Show full text]
  • Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
    processes Review Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development Outi M. H. Salo-Ahen 1,2,* , Ida Alanko 1,2, Rajendra Bhadane 1,2 , Alexandre M. J. J. Bonvin 3,* , Rodrigo Vargas Honorato 3, Shakhawath Hossain 4 , André H. Juffer 5 , Aleksei Kabedev 4, Maija Lahtela-Kakkonen 6, Anders Støttrup Larsen 7, Eveline Lescrinier 8 , Parthiban Marimuthu 1,2 , Muhammad Usman Mirza 8 , Ghulam Mustafa 9, Ariane Nunes-Alves 10,11,* , Tatu Pantsar 6,12, Atefeh Saadabadi 1,2 , Kalaimathy Singaravelu 13 and Michiel Vanmeert 8 1 Pharmaceutical Sciences Laboratory (Pharmacy), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland; ida.alanko@abo.fi (I.A.); rajendra.bhadane@abo.fi (R.B.); parthiban.marimuthu@abo.fi (P.M.); atefeh.saadabadi@abo.fi (A.S.) 2 Structural Bioinformatics Laboratory (Biochemistry), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland 3 Faculty of Science-Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, 3584 CH Utrecht, The Netherlands; [email protected] 4 Swedish Drug Delivery Forum (SDDF), Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, 751 23 Uppsala, Sweden; [email protected] (S.H.); [email protected] (A.K.) 5 Biocenter Oulu & Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7 A, FI-90014 Oulu, Finland; andre.juffer@oulu.fi 6 School of Pharmacy, University of Eastern Finland, FI-70210 Kuopio, Finland; maija.lahtela-kakkonen@uef.fi (M.L.-K.); tatu.pantsar@uef.fi
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • Preorganization of Molecular Binding Sites in Designed Diiron Proteins
    Preorganization of molecular binding sites in designed diiron proteins Ornella Maglio*, Flavia Nastri*, Vincenzo Pavone*, Angela Lombardi*†, and William F. DeGrado†‡ *Department of Chemistry, University of Napoli Federico II, Complesso Universitario Monte S. Angelo, I-80126 Napoli, Italy; and ‡Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6059 Contributed by William F. DeGrado, February 6, 2003 De novo protein design provides an attractive approach to criti- (Dueferri 1) (7–10). This protein is a small, 48-residue ho- cally test the features that are required for metalloprotein struc- modimeric model for the family of O2-using diiron proteins ture and function. Previously we designed and crystallographi- that includes methane monooxygenase and the radical-form- cally characterized an idealized dimeric model for the four-helix ing R2 subunit of the ribonucleotide reductase from Esche- bundle class of diiron and dimanganese proteins [Dueferri 1 richia coli (11–14). The DF1 dimer comprises two nonco- (DF1)]. Although the protein bound metal ions in the expected valently associated helix–loop–helix motifs that bind the manner, access to its active site was blocked by large bulky hy- diiron cofactor near the center of the protein (8). The crystal- drophobic residues. Subsequently, a substrate-access channel lographic structures of di-Zn(II) (8) and di-Mn(II) DF1 (un- was introduced proximal to the metal-binding center, resulting published results) are very similar to the di-Mn(II) and di- in a protein with properties more closely resembling those of Fe(II) forms of other natural diiron proteins (15–18).
    [Show full text]
  • 595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs
    Food and Drug Administration, HHS § 441.20a (6) pH. Proceed as directed in § 436.202 imipenem per milliliter at 25 °C is ¶85° of this chapter, using an aqueous solu- to ¶95° on an anhydrous basis. tion containing 60 milligrams per mil- (vi) It gives a positive identity test. liliter. (vii) It is crystalline. (7) Penicillin G content. Proceed as di- (2) Labeling. It shall be labeled in ac- rected in § 436.316 of this chapter. cordance with the requirements of (8) Crystallinity. Proceed as directed § 432.5 of this chapter. in § 436.203(a) of this chapter. (3) Requests for certification; samples. (9) Heat stability. Proceed as directed In addition to complying with the re- in § 436.214 of this chapter. quirements of § 431.1 of this chapter, [42 FR 59873, Nov. 22, 1977; 43 FR 2393, Jan. 17, each such request shall contain: 1978, as amended at 45 FR 22922, Apr. 4, 1980; (i) Results of tests and assays on the 50 FR 19918, 19919, May 13, 1985] batch for potency, sterility, pyrogens, loss on drying, specific rotation, iden- PART 441ÐPENEM ANTIBIOTIC tity, and crystallinity. DRUGS (ii) Samples, if required by the Direc- tor, Center for Drug Evaluation and Subpart AÐBulk Drugs Research: (a) For all tests except sterility: 10 Sec. 441.20a Sterile imipenem monohydrate. packages, each containing approxi- mately 500 milligrams. Subpart BÐ[Reserved] (b) For sterility testing: 20 packages, each containing equal portions of ap- Subpart CÐInjectable Dosage Forms proximately 300 milligrams. 441.220 Imipenem monohydrate-cilastatin (b) Tests and methods of assayÐ(1) Po- sodium injectable dosage forms.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Use of Long Half-Life Parenteral Cephalosporins in Ambulatory Practice
    Use of Long Half-Life Parenteral Cephalosporins in Ambulatory Practice Mark Sauerwein, MD, Robert L. Deamer, PharmD, and John G. Prichard, MD Ventura, California, and Houston, Texas Cefonicid (Monocid) and ceftriaxone (Rocephin) are long half-life cephalos­ porins that may be used for serious infections in the outpatient setting. They may be used as an extension of initial hospital treatment, or therapy can be initiated and completed in many cases with the patient remaining at home. Sufficient clinical experience exists with both ceftriaxone and cefonicid to recommend these agents for selected patients having pyelonephritis, os­ teomyelitis, or soft tissue infections. Cefonicid, perhaps in combination with erythromycin, will provide excellent coverage for complicated community- acquired pneumonias. Ceftriaxone is effective as single-dose therapy for even complicated gonococcal infections. The use of long half-life cephalo­ sporins in ambulatory practice may result in substantial cost savings for certain patients. linicians are at times frustrated by prolonged management of selected infections are herein re­ C hospitalizations of those who are not acutely ill viewed. simply to provide parenteral antibiotic therapy. Pa­ Cefonicid (Monocid, Smith Kline & French) is a tients and their families may be equally disconcerted broad-spectrum cephalosporin that because of its because of the high cost and disruption consequent to spectrum of activity is typically grouped as a second- hospitalization. Nevertheless, the physician may wish generation agent. Cefonicid is usually administered in­ to initiate parenteral antibiotic therapy for a particular travenously or intramuscularly in doses of 1 to 2 g, and illness, such as pyelonephritis or pneumonia, as the because of its extended four-hour half-life, it can be clinical circumstances can create apprehension about given once every 24 hours (Table 1).
    [Show full text]
  • Antimicrobial Stewardship Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use
    NICE Medicines and prescribing centre DRAFT for consultation Antimicrobial stewardship Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use Medicines practice guideline Appendices August 2015 National Institute for Health and Care Excellence Disclaimer This guideline represents the views of NICE and was arrived at after careful consideration of the evidence available. Those working in the NHS, local authorities, the wider public, voluntary and community sectors and the private sector should take it into account when carrying out their professional, managerial or voluntary duties. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Copyright National Institute for Health and Care Excellence 2015 Declarations of interest Contents Appendices .......................................................................................................................... 5 Appendix A: Declarations of interest ............................................................................ 5 A.1 Guideline development group (GDG) members .............................................. 5 A.2
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • In Silico and in Vitro Screening of FDA-Approved Drugs for Potential Repurposing Against Tuberculosis
    bioRxiv preprint doi: https://doi.org/10.1101/228171; this version posted December 3, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. In silico and in vitro screening of FDA-approved drugs for potential repurposing against tuberculosis Sridharan Brindha1, Jagadish Chandrabose Sundaramurthi2, Savariar Vincent1, Devadasan Velmurugan3, John Joel Gnanadoss1* 1Loyola College, Nungambakkam, Chennai 600034, Tamil Nadu, India 2National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai 600031, Tamil Nadu, India 3CAS in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai – 600025, Tamil Nadu, India *Corresponding Author: Dr. John Joel Gnanadoss Assistant Professor Department of Biotechnology Loyola College (University of Madras) Nungambakkam, Chennai – 600034 Tamil Nadu, India. Phone: 9840985870 E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/228171; this version posted December 3, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Motivation Repurposing of known drugs to newer clinical conditions is a promising avenue for finding novel therapeutic applications for tuberculosis. Methods We performed docking-based virtual screening for 1554 known drugs against two of the potential drug targets, namely trpD and coaA of M. tuberculosis. In the first round of in silico screening we used rigid docking using Glide and AutoDock Vina. We subjected the consistently ranked drugs for induced-fit docking by these tools against the same target proteins. We performed luciferase reporter phage (LRP) assay to determine the biological activity of five selected drugs against M.
    [Show full text]
  • Homopharma: a New Concept for Exploring the Molecular Binding
    Chiu et al. BMC Genomics 2014, 15(Suppl 9):S8 http://www.biomedcentral.com/1471-2164/15/S9/S8 RESEARCH Open Access Homopharma: A new concept for exploring the molecular binding mechanisms and drug repurposing Yi-Yuan Chiu1, Jen-Hu Tseng1, Kuan-Hsiu Liu1, Chih-Ta Lin1, Kai-Cheng Hsu1, Jinn-Moon Yang1,2* From Asia Pacific Bioinformatics Network (APBioNet) Thirteenth International Conference on Bioinformatics (InCoB2014) Sydney, Australia. 31 July - 2 August 2014 Abstract Background: Drugs that simultaneously target multiple proteins often improve efficacy, particularly in the treatment of complex diseases such as cancers and central nervous system disorders. Many approaches have been proposed to identify the potential targets of a drug. Recently, we have introduced Space-Related Pharmamotif (SRPmotif) method to recognize the proteins that share similar binding environments. In addition, compounds with similar topology may bind to similar proteins and have similar protein-compound interactions. However, few studies have focused on exploring the relationships between binding environments and protein-compound interactions, which is important for understanding molecular binding mechanisms and helpful to be used in discovering drug repurposing. Results: In this study, we propose a new concept of “Homopharma”, combining similar binding environments and protein-compound interaction profiles, to explore the molecular binding mechanisms and drug repurposing. A Homopharma consists of a set of proteins which have the conserved binding environment and a set of compounds that share similar structures and functional groups. These proteins and compounds present conserved interactions and similar physicochemical properties. Therefore, these compounds are often able to inhibit the proteins in a Homopharma. Our experimental results show that the proteins and compounds in a Homopharma often have similar protein-compound interactions, comprising conserved specific residues and functional sites.
    [Show full text]